All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.

2024-05-16T12:40:36.000Z

CheckMate 436: Nivolumab plus brentuximab vedotin for R/R PTCL and CTCL

May 16, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the treatment of peripheral T-cell lymphoma or cutaneous T-cell lymphoma.

Bookmark this article

Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL) have poor outcomes.1  Overexpression of PD-L1 and CD30 is often observed in patients with PTCL (15–41% and 46–100%, respectively) and CTCL (27–73% and 47–76%, respectively).1 Nivolumab is a checkpoint inhibitor that targets PD-1/PD-L1 binding, and brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate.1 BV was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with CTCL, based on results from the phase III ALCANZA trial (NCT01578499) which were previously reported by the Lymphoma Hub.1

Zinzani et al.1 recently published an analysis of nivolumab plus BV in PTCL and CTCL cohorts of the phase I/II CheckMate 436 trial (NCT02581631) in Blood Advances, which we summarize below.

Study design1

  • The phase I/II CheckMate 436 trial included adult patients with R/R PTCL or CTCL who had received ≥1 prior line of therapy.
  • Patients received 240 mg nivolumab on Day 8 of Cycle 1, and Day 1 of each subsequent 3-week cycle, plus 1.8 mg/kg BV intravenously on Day 1 of each cycle until progressive disease or unacceptable toxicity.
  • The primary endpoint was overall response rate.

Key findings1

Patient characteristics

  • In total, 62 patients with PTCL (n = 33) and CTCL (n = 29) received treatment
  • The median age was 60 years and 61 years in the PTCL and CTCL cohorts, respectively

Efficacy

  • In the PTCL and CTCL cohorts:
    • the median follow-up was 9.6 months and 24.4 months, respectively;
    • the median duration of response was 4.6 months and 27.0 months, respectively;
    • median progression-free survival was 4.3 and 15.6 months, respectively; and
    • median overall survival was 11.1 and 37.2 months, respectively.

Response rates for the PTCL and CTCL cohorts are shown in Figure 1.

Figure 1. Response rates after nivolumab plus brentuximab vedotin treatment* 

CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma.
*Data from Zinzani, et al.1

Safety

  • In the PTCL cohort:
    • Overall, 84.8% of patients experienced any grade treatment-related adverse events (TRAEs), most commonly fatigue (24.2%)
    • Grade 3/4 TRAEs occurred in 45.5% of patients, most commonly neutropenia (15.2%)
    • In total, one patient experienced Grade 5 treatment-related pneumonitis
  • In the CTCL cohort:
    • Overall, 89.7% of patients experienced any grade TRAEs, most commonly peripheral neuropathy (27.6%).
    • Grade 3/4 TRAEs were reported in 44.8% of patients, of which 13.8% were skin-related.
    • Overall, 40 deaths were reported in the PTCL (n = 26) and CTCL (n = 14) cohorts, most commonly due to progressive disease (n = 21 and n = 11, respectively). One death was due to treatment-related Grade 5 pneumonitis in the PTCL cohort.
Key learnings
  • The ORR observed with nivolumab plus BV in this analysis was similar to previous studies investigating PD-1 inhibitor monotherapies in patients with PTCL and CTCL; therefore, these results do not support the use of nivolumab plus BV in this patient population.
  • Further studies are warranted to identify which disease subtypes may benefit from this combination therapy.

  1. Zinzani PL, Salles GA, Moskowitz AJ, et al. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Advances. Online ahead of print. DOI: 10.1182/bloodadvances.2023011030

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

On average, how many patients with non-Hodgkin lymphoma do you see in a month?
8 votes - 15 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox